Compare CKX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | EVAX |
|---|---|---|
| Founded | 1930 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 25.9M |
| IPO Year | 1996 | 2020 |
| Metric | CKX | EVAX |
|---|---|---|
| Price | $10.70 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 4.5K | ★ 11.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1125.00 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $838,543.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | $117.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $2.52 |
| 52 Week High | $13.00 | $12.15 |
| Indicator | CKX | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 61.23 |
| Support Level | $10.21 | $2.93 |
| Resistance Level | $11.31 | $3.61 |
| Average True Range (ATR) | 0.51 | 0.16 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 26.60 | 83.61 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way, and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. It has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Timber segment.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.